News
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC
Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...
Artificial intelligence (AI) has the potential to deliver personalized nutrition; however, there is a need for professional oversight, emphasized Julia Logan, BS.
John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results